Patients appear to be at higher risk of heart problems or stroke when prescriptions for the newest cholesterol-lowering drugs are rejected by insurance companies or unfilled by patients, according to new research in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal. The drugs, PCSK9 inhibitors (PCSK9i), can substantially lower levels of low-density lipoprotein… Continue reading Rejected and Unfilled Prescriptions for New, Pricier Cholesterol Drugs Tied to Higher Heart, Stroke Risk